Wall Street analysts expect Danaher Co. (NYSE:DHR) to post earnings of $1.01 per share for the current quarter, Zacks reports. Six analysts have made estimates for Danaher’s earnings. The highest EPS estimate is $1.02 and the lowest is $0.98. Danaher reported earnings of $0.99 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 2%. The firm is expected to report its next earnings results on Thursday, April 18th.
On average, analysts expect that Danaher will report full year earnings of $4.76 per share for the current financial year, with EPS estimates ranging from $4.50 to $4.83. For the next fiscal year, analysts forecast that the business will post earnings of $5.24 per share, with EPS estimates ranging from $5.06 to $5.66. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Danaher.
Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 29th. The conglomerate reported $1.28 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.01. The business had revenue of $5.40 billion during the quarter, compared to the consensus estimate of $5.33 billion. Danaher had a return on equity of 11.64% and a net margin of 13.33%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 earnings per share.
In other news, EVP Daniel L. Comas sold 97,357 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $127.04, for a total transaction of $12,368,233.28. Following the completion of the sale, the executive vice president now owns 134,039 shares in the company, valued at $17,028,314.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Rainer Blair sold 37,859 shares of the company’s stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $127.45, for a total value of $4,825,129.55. Following the sale, the insider now owns 32,661 shares of the company’s stock, valued at approximately $4,162,644.45. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 183,150 shares of company stock valued at $23,279,637. Corporate insiders own 11.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in DHR. Laurel Wealth Advisors LLC bought a new stake in Danaher during the fourth quarter worth $27,000. Hanson McClain Inc. grew its holdings in Danaher by 852.9% during the fourth quarter. Hanson McClain Inc. now owns 324 shares of the conglomerate’s stock worth $33,000 after buying an additional 290 shares in the last quarter. Executive Wealth Management LLC bought a new stake in Danaher during the fourth quarter worth $39,000. Ruggie Capital Group bought a new stake in Danaher during the fourth quarter worth $40,000. Finally, We Are One Seven LLC bought a new stake in Danaher during the fourth quarter worth $44,000. Institutional investors and hedge funds own 76.90% of the company’s stock.
DHR stock traded up $0.58 during mid-day trading on Friday, reaching $125.04. The company’s stock had a trading volume of 2,369,099 shares, compared to its average volume of 3,110,423. The company has a market cap of $79.54 billion, a P/E ratio of 27.66, a PEG ratio of 1.97 and a beta of 0.99. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.07 and a current ratio of 1.47. Danaher has a 12 month low of $94.59 and a 12 month high of $128.39.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.17 per share. This is an increase from Danaher’s previous quarterly dividend of $0.16. This represents a $0.68 annualized dividend and a dividend yield of 0.54%. Danaher’s payout ratio is currently 14.16%.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.